The invention provides a baricitinib polymorph A. The baricitinib polymorph A is characterized in that diffraction peaks are arranged on an XRPD (X Ray Powder Diffraction) map when values of 2 theta are equal to 12.46, 13.921, 14.94, 15.359, 16.26, 16.639, 17.36, 19.08, 20.321, 21.961, 22.381, 24.118, 25.42, 27.441, 28.381, 29.321, 29.799, 32.675, 33.14, 33.563, 33.923 and 41.6, wherein an error range of the values of the 2 theta is +/- 0.2. The baricitinib polymorph A provided by the invention has good high-temperature stability, good high-humidity stability and good illumination stability, can be applied to medicine for treating or preventing diseases related to JAK (Janus Kinase) and has better biological availability; meanwhile, provided qualitative and quantitative information has important significance in further studying the therapeutic effect of such solid medicine.